Immix Biopharma (IMMX) Change in Accured Expenses (2021 - 2026)

Immix Biopharma has reported Change in Accured Expenses for 6 years, with the latest figure at $432207.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 67.06% year-over-year to $432207.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 56.11% YoY) and the FY2025 annual result came in at $1.0 million, down 76.66% from the prior year.
• Change in Accured Expenses advanced to $432207.0 in Q1 2026 per IMMX's latest filing, from -$790864.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.3 million in Q4 2024 and troughed at -$1.8 million in Q2 2024.
• A 5-year average of $487432.9 and a median of $451957.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 61850.0% in 2023, then slumped 292.53% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$516044.0 in 2022, then jumped by 265.53% to $854219.0 in 2023, then surged by 167.04% to $2.3 million in 2024, then tumbled by 134.67% to -$790864.0 in 2025, then soared by 154.65% to $432207.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $432207.0, -$790864.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.